Pharmacist-Led Full-Course Pharmaceutical Care Model in Allergic Bronchopulmonary Aspergillosis: A Case Report-Based...

The management of allergic bronchopulmonary aspergillosis (ABPA) is complicated by prolonged, multi-drug regimens that carry a high risk of multi-system adverse drug reactions (ADRs). This complexity underscores the need for integrated, continuous pharmaceutical care to optimize safety and efficacy, yet standardized models for such care are lacking.

We report the case of a patient with ABPA and comorbid chronic hepatitis B, who had a history of failed ABPA therapy. During the current therapeutic course, the patient not only sequentially developed steroid-induced diabetes, drug-induced liver injury, hyperlactatemia, visual disturbances, phototoxicity, and hypokalemia but also progressed to treatment-dependent ABPA. The patient successfully completed the over-two-year protocol through a pharmacist-led full-course pharmaceutical care model that integrated regimen evaluation, efficacy monitoring, comprehensive adverse reaction management, discharge education, and follow-up.

This case demonstrates that a full-course pharmaceutical care model enables timely detection and management of complex ADRs, optimizes therapeutic outcomes, and supports multidisciplinary decision-making. The model illustrates the pivotal role of the clinical pharmacist in improving medication safety and efficacy in ABPA, offering a replicable framework for promoting integrated, patient-centered care in pulmonary fungal diseases.